Droia Ventures
VC Fund
Luxembourg, Luxembourg
Droia Ventures is a VC fund in Luxembourg focused on Biotechnology and Medical. Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs, andinvestment professionals we build great companies to save patient lives.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $267M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Droia Ventures invests in
Stages Droia Ventures invests in
Countries Droia Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $12M–$75M
- Series B
- $29M–$130M
- Series C
- $75M–$125M
Investment Focus
Industry
- Biotechnology 23 (56%)
- Medical 12 (29%)
- Therapeutics 9 (22%)
- Health Care 8 (20%)
- Pharmaceutical 8 (20%)
Stage
- Series A 13 (32%)
- Series B 9 (22%)
- Series C 6 (15%)
- Seed 4 (10%)
- Funding Round 2 (5%)
Country
- United States 16 (39%)
- Belgium 3 (7%)
- The Netherlands 3 (7%)
- Denmark 1 (2%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
George Golumbeski
Partner
|
Partner | Total investments: 5 | Find email | |
Luc Verelst
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email | |
Thomas Martz
Entrepreneur-In-Residence
|
Entrepreneur-In-Residence | Total investments: 0 | Find email | |
Bart Van Hooland
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases. | $152M / Series B / Aug 11, 2026 | ||
| Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California. | $45M / Series B / Mar 16, 2026 | ||
| Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | ||
| Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients. | $66M / Series B / Jun 18, 2025 | ||
| Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases. | $67M / Series A / Mar 25, 2025 | ||
| Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic approaches to treat cancer | $67M / Series A / Jan 08, 2025 | ||
| Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $75M / Series A / Oct 07, 2024 | ||
| Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $12.3M / Series B / Jun 24, 2024 | ||
| Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $80M / Series C / Feb 22, 2024 | ||
| Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients. | $75M / Series C / Jan 23, 2024 | ||
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Droia Ventures invest in?
Droia Ventures invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Droia Ventures invest in?
Droia Ventures typically joins rounds of $12M–$75M at Series A, $29M–$130M at Series B and $75M–$125M at Series C. These are whole funding-round sizes, not Droia Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Droia Ventures took part in.
How do I contact Droia Ventures?
Public channels for Droia Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Droia Ventures?
The team at Droia Ventures includes George Golumbeski (Partner), Luc Verelst (Founder & Chairman) and Thomas Martz (Entrepreneur-In-Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
